{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/267244543"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "In particular, Tyco alleged that ???the safety and efficacy of Restoril was likely linked to its pharmacokinetic profile, and that changes to parameters such as specific surface area in a generic version could alter that profile and thereby affect the safety and efficacy of the generic version as compared to Restoril.??? Thus, Tyco urged the FDA to adopt proposed guidelines that ???would require g" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "jdsupra.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/285364236"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/267244543"] } } }
